"Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic"
Related Experiment Video
Updated: Nov 20, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
1From the National Cancer Institute, Bethesda, MD.
Abstract:
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers and has an incidence as high as 50% of brain metastases once patients develop advanced disease. The lack of targeted and effective therapies, characteristic of this subtype of breast cancer, is especially evident once central nervous system (CNS) metastases occur. Compared with other subtypes of breast cancer, TNBC patients have the shorter interval from diagnosis to development of brain metastases and the shorter overall survival once they occur, a median of 4 to 6 months. Preclinical studies of TNBC and CNS microenvironment are actively ongoing, clarifying mechanisms and orienting more effective approaches to therapy. While the first drugs have been specifically approved for use in metastatic TNBC, data on their CNS effect are still awaited.
Insights
Triple-negative breast cancer (TNBC) frequently metastasizes to the brain, lacking effective treatments. Research is ongoing to understand TNBC brain metastases and develop targeted therapies for better patient outcomes.
Area of Science:
- Oncology
- Neuro-oncology
- Cancer Metastasis
Background:
- Triple-negative breast cancer (TNBC) represents 15-20% of all breast cancers.
- TNBC is associated with a high incidence (up to 50%) of brain metastases in advanced stages.
- This subtype lacks targeted therapies, particularly for central nervous system (CNS) involvement.
Purpose of the Study:
- To highlight the challenges in treating TNBC brain metastases.
- To underscore the need for understanding the TNBC CNS microenvironment.
- To inform the development of more effective therapeutic strategies.
Main Methods:
- Review of current understanding of TNBC and CNS metastases.
- Analysis of survival data for TNBC patients with brain metastases.
- Monitoring of ongoing preclinical research into TNBC and CNS microenvironment.
Main Results:
- TNBC patients experience a shorter interval to brain metastasis development compared to other breast cancer subtypes.
- Overall survival for TNBC patients with brain metastases is poor, averaging 4-6 months.
- Preclinical studies are actively investigating mechanisms of TNBC brain metastasis.
Conclusions:
- Effective therapies for TNBC, especially with CNS involvement, remain a critical unmet need.
- Further research into the CNS microenvironment is crucial for advancing treatment approaches.
- Data on the efficacy of newly approved metastatic TNBC drugs in the CNS are pending.
